CTMX · CytomX Therapeutics, Inc.
$3.31
-0.01 (-0.30%)
At close · Aug 27
Market Cap
$734.32M
Shares
217.90M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. Chief Executive Officer and Chairman of the Board of Directors | $2,611,138 |
| Marcia P. Belvin | Senior Vice President, and Chief Scientific Officer | $1,206,347 |
| Jeff Landau | Senior Vice President and Chief Business Officer | $1,047,812 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. Chief Executive Officer and Chairman of the Board of Directors | $3,013,606 |
| Carlos Campoy | Former Senior Vice President and Chief Financial Officer | $1,420,271 |
| Lloyd A. Rowland | Senior Vice President, | $1,205,166 |
| Jeff Landau | Senior Vice President and Chief Business Officer | $1,060,903 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. Chief Executive Officer and Chairman of the Board of Directors | $4,339,415 |
| Amy Peterson | Former President and Chief Operating Officer | $2,252,280 |
| Jeff Landau | Senior Vice President and Chief Business Officer | $1,755,321 |
| Alison L. Hannah | Senior Vice President and Chief Medical Officer | $1,707,176 |
| Lloyd A. Rowland | Senior Vice President, | $1,421,758 |
| Carlos Campoy | Former Senior Vice President and Chief Financial Officer | $1,396,204 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. Chief Executive Officer and Chairman of the Board of Directors | $2,849,850 |
| Carlos Campoy | Senior Vice President, Chief Financial Officer | $1,741,639 |
| Alison L. Hannah | Senior Vice President and Chief Medical Officer | $1,677,988 |
| Lloyd A. Rowland | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | $953,393 |
| Amy Peterson | President, Chief Operating Officer | $899,442 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. Chief Executive Officer and Chairman of the Board of Directors | $3,769,930 |
| Amy Peterson | President, Chief Operating Officer | $3,395,723 |
| Rachel Humphrey | Former Senior Vice President and Chief Medical Officer | $1,871,354 |
| W. Michael Kavanaugh | Former Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | $1,476,997 |
| Lloyd A. Rowland | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | $1,097,843 |
| Debanjan Ray | Former Senior Vice President and Chief Financial Officer | $1,063,677 |
| Carlos Campoy | Senior Vice President, Chief Financial Officer | — |
| Alison L. Hannah | Senior Vice President and Chief Medical Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | $5,482,233 |
| Rachel Humphrey | Former Senior Vice President and Chief Medical Officer | $2,290,819 |
| Debanjan Ray | Former Senior Vice President and Chief Financial Officer | $2,100,385 |
| W. Michael Kavanaugh | Former Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | $1,774,606 |
| Lloyd A. Rowland | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | $26,586 |
| Amy Peterson | Executive Vice President, Chief Development Officer | — |
| Carlos Campoy | Senior Vice President, Chief Financial Officer | — |
| Alison L. Hannah | Senior Vice President and Chief Medical Officer | — |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Sean McCarthy | D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | $3,213,339 |
| Rachel Humphrey | Former Senior Vice President and Chief Medical Officer | $1,609,345 |
| Debanjan Ray | Former Senior Vice President and Chief Financial Officer | $1,563,122 |
| W. Michael Kavanaugh | Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | $1,499,744 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Fuchs, M.D., M.P.H. | Class II director | Appointed | 2026-07-27 |
| Elaine V. Jones Ph.D. | Class II director | Appointed | 2026-06-22 |
| Matthew P. Young | Class II director | Appointed | 2026-06-22 |
| Zhen Su, M.D., M.B.A. | Class I director | Appointed | 2025-06-13 |
| Mani Mohindru, Ph.D. | Class I director | Appointed | 2025-06-13 |
| Sean A. McCarthy, D. Phil. | Class I director | Appointed | 2025-06-13 |
| Jeffrey Landau | Senior Vice President, Chief Business Officer, and Head of Strategy | Terminated | 2025-02-03 |
| Chris Ogden | Chief Financial Officer | Appointed | 2024-06-17 |
| Zhen Su, M.D., M.B.A. | Class I director | Appointed | 2024-03-22 |
| Carlos Campoy | SVP, Chief Financial Officer | Terminated | 2022-09-23 |
| Alison Hannah, M.D. | SVP, Chief Medical Officer | Terminated | 2022-07-13 |
| Carlos Campoy | SVP, Chief Financial Officer | Terminated | 2022-07-13 |
| Amy Peterson, M.D. | President and Chief Operating Officer | Terminated | 2022-07-13 |
| John A. Scarlett, M.D. | director | Retired | 2022-04-14 |
| Frederick W. Gluck | board of directors | Retired | 2022-03-23 |
| Chris Ogden | interim principal accounting officer | Appointed | 2022-02-14 |
| Amy Peterson | President and Chief Operating Officer | Appointed | 2022-02-07 |
| Alan Ashworth, Ph.D., FRS | Class III director | Appointed | 2021-10-04 |
| Mani Mohindru | Class I director | Appointed | 2020-12-22 |
| Michael Kavanaugh, M.D. | SVP, Chief Scientific Officer, Head of Research and Non-Clinical Development | Retired | 2020-10-06 |
| Halley Gilbert | Class III director | Appointed | 2020-04-28 |
| Carlos Campoy | Senior Vice President and Chief Financial Officer | Appointed | 2020-03-23 |
Key facts
CIK
1501989
CUSIP
23284F105
13F (30d)
170 filings
166 filers
Visit website
Investor relations